BioSpace News Archive

Researchers will be presenting these prostate cancer study findings at the 117th Annual Scientific Meeting of the American Urological Association.

Orphazyme A/S in restructuring, a late-stage biopharmaceutical company developing arimoclomol for Niemann-Pick disease type C, announces that it has signed an agreement to sell substantially all of the Company’s assets and business activities to KemPharm Denmark A/S, a wholly owned subsidiary of KemPharm Inc.

Zenas BioPharma announced the submission of an investigational new drug application to the China National Medical Products Administration for the initiation of a Phase 1/2 clinical study of ZB001 for the treatment of Thyroid Eye Disease.

ReCode Therapeutics, a biopharmaceutical company powering the next wave of genetic medicines through superior delivery presented new preclinical data from the company’s inhaled mRNA-based molecular therapy program for the treatment of primary ciliary dyskinesia in three posters at the American Thoracic Society 2022 International Conference, taking place May 13-18, 2022 in San Francisco.

KemPharm, Inc. announced a definitive agreement with Orphazyme A/S to acquire arimoclomol, an orally-delivered, first-in-class heat shock protein amplifier being developed as a treatment for Niemann-Pick disease type C.

Antengene Corporation Limited announces that its first commercialized product, the oral XPO1 inhibitor XPOVIO® approved for the treatment of relapsed/refractory multiple myeloma, has officially entered multiple hospitals, online-hospitals, and direct-to-patient pharmacies in mainland China.